Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Chronic kidney disease (CKD) and related oxidative stress can dysregulate the nitric oxide (NO)/soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP) pathway, leading to reduced cGMP production. Insufficient cGMP levels are detrimental to the cardiovascular system and kidneys, accelerating renal damage and CKD progression. Runcaciguat, a novel sGC activator, shows strong potential as an effective treatment for CKD associated with hypertension, diabetes, or obesity. It selectively binds to oxidized and/or heme-free sGC under oxidative stress, enhancing cGMP production and exhibiting favorable pharmacokinetics with once-daily dosing. The aim of this study was to evaluate the effectiveness of runcaciguat alone or in combination with an SGLT2 inhibitor (empagliflozin) in a rat model of hypertension with CKD.
Ren-2 transgenic rats (TGR), carrying an additional renin gene, were used as a model of hypertension with a defined genetic background. At 7–8 weeks of age, animals underwent subtotal 5/6 nephrectomy (5/6 Nx) to induce CKD. Four weeks later, treatment with runcaciguat (RUNCA) alone or combined with empagliflozin (RUNCA+EMPA) was initiated and continued for 15 weeks. Blood and urine were collected for analysis of renal biomarkers. In the end rats were decapitated, organs were weighed and collected for further analysis.
After 15 weeks, survival in untreated Nx TGR was 56%, whereas survival in the RUNCA-treated group remained 100%. One rat died in the sham TGR control group and one in the Nx TGR RUNCA+EMPA group. Runcaciguat significantly improved kidney function, as shown by reduced albuminuria, prevention of plasma albumin decline, decreased blood urea nitrogen, and increased creatinine clearance. There was no further improvement with empagliflozin.
Runcaciguat markedly improved renal function and survival in hypertensive CKD rats. These findings support further long-term studies to confirm its renoprotective potential.
